Nakhleh R E, Jones B, Zarbo R J
Department of Pathology, Henry Ford Hospital, Detroit, Mich. 48202, USA.
Arch Pathol Lab Med. 1997 Jan;121(1):11-8.
To determine (1) the information that clinical physicians want in surgical pathology reports of biopsies performed for mammographic abnormalities, (2) how specimens are received and processed, and (3) what information is actually present in pathology reports.
The standard data collection and questionnaire format of the College of American Pathologists' Q-Probes quality improvement program was used. Laboratories (1) surveyed clinical physicians working in selected specialties involved in the care of patients with breast disease concerning what information they wanted in a surgical pathology report, (2) documented laboratory specimen handling for 20 consecutive breast biopsy tissues obtained to investigate mammographic abnormalities, and (3) documented the information content of surgical pathology reports of these cases.
Four hundred thirty-four participating laboratories surveyed 1469 clinical physicians and collected information on 7300 cases regarding specimen processing and report content.
Clinical physicians were unanimous in the majority of items they desired for patient care. The information, however, differed depending on the diagnosis. In processing of tissues, 89% of specimens were received without fixative. In 83% of cases, radiographs were performed. Eighty-two percent of specimens were marked in some manner, but in only 45% of cases was a report of the radiographic abnormality given to the Pathology Department. The median number of blocks used to sample the lesion and the whole specimen was three and six blocks, respectively. The latter correlated with specimen size. Fifty-seven (13%) surgical pathology laboratories had radiography equipment. Radiographs of specimens and tissue blocks were made in 5% and 4% of cases, respectively. Correlation of a mammographic abnormality with a microscopic finding was documented in 62% of reports. In 92% of malignant cases the margin status was reported, and 77% of reports contained the lesion size. Eighty-three percent of reports with invasive carcinoma stated the tumor grade, and 76% stated the extent of intraductal carcinoma. The percentage of reports containing information items was significantly higher (P < .05) for institutions using checklists.
This multi-institutional Q-Probes study describes the current clinical expectations and laboratory practices associated with mammographically directed biopsies. Disparities between pathology reporting and clinician desires, as well as radiology and laboratory specimen handling practices, have been identified and may help focus future quality improvement efforts.
确定(1)临床医生在针对乳腺钼靶异常进行活检的手术病理报告中想要的信息,(2)标本的接收和处理方式,以及(3)病理报告中实际包含的信息。
采用美国病理学家学会Q-Probes质量改进计划的标准数据收集和问卷形式。实验室(1)就手术病理报告中他们想要的信息,对从事乳腺疾病患者护理工作的特定专业的临床医生进行调查,(2)记录连续获取的20例用于调查乳腺钼靶异常的乳腺活检组织的实验室标本处理情况,以及(3)记录这些病例手术病理报告的信息内容。
434个参与实验室调查了1469名临床医生,并收集了7300例关于标本处理和报告内容的信息。
临床医生在大多数他们期望用于患者护理的项目上意见一致。然而,信息因诊断而异。在组织处理方面,89%的标本接收时没有固定剂。83%的病例进行了X光片检查。82%的标本以某种方式做了标记,但只有45%的病例将X光片异常报告给了病理科。用于对病变和整个标本取样的蜡块中位数分别为3块和6块。后者与标本大小相关。57个(13%)手术病理实验室有X光检查设备。分别在5%和4%的病例中对标本和组织蜡块进行了X光片拍摄。62%的报告记录了乳腺钼靶异常与显微镜下发现的相关性。92%的恶性病例报告了切缘情况,77%的报告包含病变大小。83%的浸润性癌报告说明了肿瘤分级,76%说明了导管内癌的范围。对于使用清单的机构,包含信息项的报告百分比显著更高(P < .05)。
这项多机构Q-Probes研究描述了当前与乳腺钼靶引导活检相关的临床期望和实验室操作。已确定病理报告与临床医生期望之间的差异,以及放射学和实验室标本处理操作方面的差异,这可能有助于聚焦未来的质量改进工作。